[go: up one dir, main page]

IT202300014322A1 - GLUTATHIONE FOR USE IN THE PREVENTION AND/OR TREATMENT OF CARDIOVASCULAR AND RESPIRATORY COMPLICATIONS CONCOMITANT WITH AND/OR CONSEQUENT TO PNEUMONIA - Google Patents

GLUTATHIONE FOR USE IN THE PREVENTION AND/OR TREATMENT OF CARDIOVASCULAR AND RESPIRATORY COMPLICATIONS CONCOMITANT WITH AND/OR CONSEQUENT TO PNEUMONIA

Info

Publication number
IT202300014322A1
IT202300014322A1 IT102023000014322A IT202300014322A IT202300014322A1 IT 202300014322 A1 IT202300014322 A1 IT 202300014322A1 IT 102023000014322 A IT102023000014322 A IT 102023000014322A IT 202300014322 A IT202300014322 A IT 202300014322A IT 202300014322 A1 IT202300014322 A1 IT 202300014322A1
Authority
IT
Italy
Prior art keywords
pneumonia
glutathione
consequent
cardiovascular
prevention
Prior art date
Application number
IT102023000014322A
Other languages
Italian (it)
Inventor
Massimiliano Florio
Original Assignee
Biomedica Foscama Ind Chimico Farmaceutica S P A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomedica Foscama Ind Chimico Farmaceutica S P A filed Critical Biomedica Foscama Ind Chimico Farmaceutica S P A
Priority to IT102023000014322A priority Critical patent/IT202300014322A1/en
Priority to PCT/EP2024/069174 priority patent/WO2025012197A1/en
Publication of IT202300014322A1 publication Critical patent/IT202300014322A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IT102023000014322A 2023-07-10 2023-07-10 GLUTATHIONE FOR USE IN THE PREVENTION AND/OR TREATMENT OF CARDIOVASCULAR AND RESPIRATORY COMPLICATIONS CONCOMITANT WITH AND/OR CONSEQUENT TO PNEUMONIA IT202300014322A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IT102023000014322A IT202300014322A1 (en) 2023-07-10 2023-07-10 GLUTATHIONE FOR USE IN THE PREVENTION AND/OR TREATMENT OF CARDIOVASCULAR AND RESPIRATORY COMPLICATIONS CONCOMITANT WITH AND/OR CONSEQUENT TO PNEUMONIA
PCT/EP2024/069174 WO2025012197A1 (en) 2023-07-10 2024-07-08 Glutathione for use in the prevention and/or treatment of cardiovascular and respiratory complications concomitant with and/or consequent to pneumonia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102023000014322A IT202300014322A1 (en) 2023-07-10 2023-07-10 GLUTATHIONE FOR USE IN THE PREVENTION AND/OR TREATMENT OF CARDIOVASCULAR AND RESPIRATORY COMPLICATIONS CONCOMITANT WITH AND/OR CONSEQUENT TO PNEUMONIA

Publications (1)

Publication Number Publication Date
IT202300014322A1 true IT202300014322A1 (en) 2025-01-10

Family

ID=88413953

Family Applications (1)

Application Number Title Priority Date Filing Date
IT102023000014322A IT202300014322A1 (en) 2023-07-10 2023-07-10 GLUTATHIONE FOR USE IN THE PREVENTION AND/OR TREATMENT OF CARDIOVASCULAR AND RESPIRATORY COMPLICATIONS CONCOMITANT WITH AND/OR CONSEQUENT TO PNEUMONIA

Country Status (2)

Country Link
IT (1) IT202300014322A1 (en)
WO (1) WO2025012197A1 (en)

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0494405A2 (en) 1991-01-10 1992-07-15 Transcend Therapeutics, Inc. Use of thiazolidine-4-carboxylate derivatives for the treatment of pulmonary diseases
WO2005017094A2 (en) 2003-08-19 2005-02-24 Bioadvantex Pharma Inc. N-acetyl compositions as adjunct therapy for treatment and prevention of cysteine/glutathione deficiency
WO2014126594A1 (en) 2013-02-15 2014-08-21 Guilford Frederick Timothy Treatment of evolving bacterial resistance diseases including klebsiella pneumoniae with liposomally formulated glutathione
WO2016120787A1 (en) 2015-01-26 2016-08-04 Novartis Consumer Health S.A. Oral n-acetylcysteine in the treatment of upper respiratory tract infections and symptoms
US20210299077A1 (en) 2020-03-27 2021-09-30 Your Energy Systems, LLC Liposomal reduced glutathione (lrg) in combination with ivermectin for the treatment of covid-19
WO2021205083A2 (en) 2020-04-11 2021-10-14 Finindsutria Srl Composition for the prevention or treatment of covid-19
WO2021236958A1 (en) 2020-05-22 2021-11-25 Auro Pharmaceuticals, Inc. Compositions and methods of treatment with glutathione
WO2021252378A1 (en) 2020-06-08 2021-12-16 Nacuity Pharmaceuticals, Inc. Prevention or treatment of covid-19
WO2021263206A1 (en) 2020-06-26 2021-12-30 Prothione, Llc Compositions and methods for the treatment of covid-19
WO2022011305A2 (en) 2020-07-09 2022-01-13 Beyond Barriers Therapeutics, Inc. Intranasal administration of an antioxidant compound for treating coronavirus infection

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0494405A2 (en) 1991-01-10 1992-07-15 Transcend Therapeutics, Inc. Use of thiazolidine-4-carboxylate derivatives for the treatment of pulmonary diseases
EP0715853A1 (en) 1991-01-10 1996-06-12 Transcend Therapeutics, Inc. Use of glutathione esters for the treatment of pulmonary diseases
WO2005017094A2 (en) 2003-08-19 2005-02-24 Bioadvantex Pharma Inc. N-acetyl compositions as adjunct therapy for treatment and prevention of cysteine/glutathione deficiency
WO2014126594A1 (en) 2013-02-15 2014-08-21 Guilford Frederick Timothy Treatment of evolving bacterial resistance diseases including klebsiella pneumoniae with liposomally formulated glutathione
WO2016120787A1 (en) 2015-01-26 2016-08-04 Novartis Consumer Health S.A. Oral n-acetylcysteine in the treatment of upper respiratory tract infections and symptoms
US20210299077A1 (en) 2020-03-27 2021-09-30 Your Energy Systems, LLC Liposomal reduced glutathione (lrg) in combination with ivermectin for the treatment of covid-19
WO2021205083A2 (en) 2020-04-11 2021-10-14 Finindsutria Srl Composition for the prevention or treatment of covid-19
WO2021236958A1 (en) 2020-05-22 2021-11-25 Auro Pharmaceuticals, Inc. Compositions and methods of treatment with glutathione
WO2021252378A1 (en) 2020-06-08 2021-12-16 Nacuity Pharmaceuticals, Inc. Prevention or treatment of covid-19
WO2021263206A1 (en) 2020-06-26 2021-12-30 Prothione, Llc Compositions and methods for the treatment of covid-19
WO2022011305A2 (en) 2020-07-09 2022-01-13 Beyond Barriers Therapeutics, Inc. Intranasal administration of an antioxidant compound for treating coronavirus infection

Non-Patent Citations (26)

* Cited by examiner, † Cited by third party
Title
"Remington's pharmaceutical Science Handbook", MACK PUB.
ANONYMOUS: "Setria Glutathione: The superior antioxidant", 24 March 2023 (2023-03-24), XP093108410, Retrieved from the Internet <URL:https://web.archive.org/web/20230324232355/https://setriaglutathione.com/fr/glutathion-setria> [retrieved on 20231204] *
AROSIO, E. ET AL.: "effect of glutathione infusion on leg arterial circulation, cutaneous microcirculation, and pain-free walking distance in patients with peripheral arterial arterial disease: A randomized, double-blind, placebo-controlled trial", MAYO CLIN PROC., vol. 77, no. 8, August 2002 (2002-08-01), pages 754 - 9
BASTIN, A.J. ET AL., SYSTEMIC INFLAMMATION AND OXIDATIVE STRESS POST-LUNG DETECTION: EFFECT OF PRETREATMENT WITH NACETYLCYSTEINE, RESROLOGY, vol. 21, no. 1, 27 October 2015 (2015-10-27), pages 180 - 7
DOMENIGHETTI, G. ET AL.: "treatment with N-acetylcysteine during acute respiratory distress syndrome: A randomized, double-blind, placebo-controlled clinical study", J CRIT CARE, vol. 12, no. 4, December 1997 (1997-12-01), pages 177 - 82
DUBOIS-DERUY, E.PEUGNET, V.TURKIEH, SULL'. A.PINET, F.: "Oxidative stress in Cardiovascular diseases", ANTIOXIDANTS (BASEL, SWITZERLAND, vol. 9, no. 9, 2020, pages 864
EI-HAMAMSY, I. ET AL.: "effect of intravenous N-acetylcysteine on outcomes after coronary artery bypass surgery: A randomized, double-blind, placebo-controlled clinical trial", J THORAC CARDIOVASCULAR SURG., vol. 133, no. 1, 7 May 2006 (2006-05-07), pages 7 - 12, XP005814748, DOI: 10.1016/j.jtcvs.2006.05.070
G R BERNARD ET AL.: "A trial of antioxidants N-acetylcysteine and procysteine in ARDS", THE ANTIOXIDANT IN ARDS STUDY GROUP, CHEST, vol. 112, no. 1, July 1997 (1997-07-01), pages 164 - 72
HOROWITZ RICHARD I ET AL: "Efficacy of glutathione therapy in relieving dyspnea associated with COVID-19 pneumonia: A report of 2 cases", RESPIRATORY MEDICINE CME, ELSEVIER, AMSTERDAM, NL, vol. 30, 1 January 2020 (2020-01-01), XP086239681, ISSN: 2213-0071, [retrieved on 20200421], DOI: 10.1016/J.RMCR.2020.101063 *
KHANFAR A ET AL: "Could glutathione depletion be the Trojan horse of COVID-19 mortality?", EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, vol. 24, 1 January 2020 (2020-01-01), pages 12500 - 12509, XP093109119, Retrieved from the Internet <URL:https://www.europeanreview.org/wp/wp-content/uploads/12500-12509.pdf> *
KIM, J.C. ET AL.: "effect of N-acetylcysteine on pulmonary function in patients undergoing off-pump coronary artery bypass surgery", ACTA ANAESTESIOL SCOLD, vol. 55, no. 4, April 2011 (2011-04-01), pages 452 - 9
M A ARSTALL ET AL.: "N-acetylcysteine in combination with nitroglycerin and streptokinase for the treatment of evolving acute myocardial infarction", SAFETY AND BIOCHEMICAL EFFECTS, CLINICAL TRIAL CIRCULATION, vol. 92, no. 10, 15 November 1995 (1995-11-15), pages 2855 - 62
MAHMOUD, K.M.AMMAR, A.S: "effect of N-acetylcysteine on cardiac injury and oxidative stress after abdominal aortic aneurysm repair: A randomized controlled trial", ACTA ANAESTESIOL SOLD, vol. 55, no. 8, September 2011 (2011-09-01), pages 1015 - 21, XP071048691, DOI: 10.1111/j.1399-6576.2011.02492.x
NOZARI ET AL.: "Protection from Reperfusion injury with Intracoronary N-Acetylcysteine in patients with STEMI Undergoing Primary cutaneous Coronary intervention in a Cardiac Tertiary Center", J CARDIOVASCULAR DRUGS, vol. 18, no. 3, June 2018 (2018-06-01), pages 213 - 221
ORHAN, G. ET AL., EFFECTS OF N-ACETYLCYSTEINE ON MYOCARDIAL ISCHEMIA-REPERFUSION INJURY IN BYPASS SURGERY, HEART VESSELS, vol. 21, no. 1, January 2006 (2006-01-01), pages 42 - 7
ORTOLANI, O. ET AL.: "protective effects of N-acetylcysteine and rutin on the lipid peroxidation of the lung epithelium during the adult respiratory distress syndrome", SHOCK, vol. 13, no. 1, January 2000 (2000-01-01), pages 14 - 8
RICHIE JOHN P JR ET AL: "Randomized controlled trial of oral glutathione supplementation on body stores of glutathione", EUROPEAN JOURNAL OF NUTRITION, STEINKOPFF VERLAG, DARMSTADT, DE, vol. 54, no. 2, 5 May 2014 (2014-05-05), pages 251 - 263, XP035447180, ISSN: 1436-6207, [retrieved on 20140505], DOI: 10.1007/S00394-014-0706-Z *
SADEGH SOLTAN-SHARYFI, M.S.: "evidence for underlying toxicological mechanisms", HUM EXP TOXICOL, 2007
SILVAGNO FRANCESCA ET AL: "The Role of Glutathione in Protecting against the Severe Inflammatory Response Triggered by COVID-19", ANTIOXIDANTS, vol. 9, no. 7, 16 July 2020 (2020-07-16), pages 624, XP055911830, ISSN: 2076-3921, DOI: 10.3390/antiox9070624 *
SOLEIMANI, A. ET AL.: "the effect of intravenous N-acetylcysteine on prevention of atrial fibrillation after coronary artery bypass graft surgery: A double-blind, randomized, placebo-controlled trial", JOURNAL OF CLINICAL AND CLINICAL USE, vol. 76, no. 1, 5 October 2017 (2017-10-05), pages 923 - 9
SPEAROW JIMMY L ET AL: "Review: Improving Therapeutics for COVID-19 with Glutathione-boosting Treatments that Improve Immune Responses and Reduce the Severity of Viral Infections", 15 May 2020 (2020-05-15), XP055896145, Retrieved from the Internet <URL:https://osf.io/preprints/osf/y7wc2> DOI: 10.31219/osf.io/y7wc2 *
TAHER, A. ET AL.: "A pilot study on intravenous N-Acetylcystine treatment in patients with mild-to-moderate COVID19-associated acute respiratory distress syndrome", PHARMACOL REP, vol. 73, no. 6, 10 June 2021 (2021-06-10), pages 1650 - 1659
TANZILLI, G. ET AL.: "glutathione infusion before primary percutaneous coronary intervention: A randomized controlled pilot study", BMJ OPEN, vol. 9, no. 8, 8 August 2019 (2019-08-08), pages e025884
TORRES, A.CATIA, C.NIEDERMAN, M. S.ROSARIO, M.CHALMERS, J. D.WUNDERINK, R. G.: "pneumonia (primer", NATURE REVIEWS: DISEASE PRIMERS, vol. 7, no. 1, 2021
TOSIOS, P. ET AL.: "N-acetylcysteine prevents reactive oxygen species-mediated myocardial stress in patients undergoing cardiac surgery: results of a randomized, double-blind, placebo-controlled clinical trial", J THORAC CARDIOVASCULAR SURG., vol. 126, no. 5, November 2003 (2003-11-01), pages 1513 - 20
YESILBURSA, D. ET AL., EFFECT OF N-ACETYLCYSTEINE ON OXIDATIVE STRESS AND VENTRICULAR FUNCTION IN PATIENTS WITH MYOCARDIAL INFARCTION, HEART VESSELS, vol. 21, no. 1, January 2006 (2006-01-01), pages 33 - 7

Also Published As

Publication number Publication date
WO2025012197A1 (en) 2025-01-16

Similar Documents

Publication Publication Date Title
EP4157144A4 (en) Acute and chronic devices for modifying flow in body lumens and methods of use thereof
EP3912623C0 (en) PD-0184264 FOR THE TREATMENT OF CORONAVIRUS INFECTIONS AND/OR COVID-19 CYTOKINE STORM
EA202091389A1 (en) PROBIOTIC-BASED COMPOSITION AND ITS APPLICATION
NO20083658L (en) Cyanoisoquinoline compounds that stabilize hypoxia inducible factor (HIF)
DK2996701T3 (en) COMPOSITION INCLUDING LACTIC ACID BACTERIA FOR USE IN THE PREVENTATIVE AND / OR HEALING TREATMENT OF BACTERIAL VAGINOSIS
GB2608591B (en) Implementation of pooling and unpooling or reverse pooling in hardware
EP4271946A4 (en) AIR PURIFICATION AND SURFACE STERILIZATION SYSTEMS AND FURNITURE SYSTEMS THAT CAN BE INTEGRATED INTO BUILDING STRUCTURES
BR112013029672A2 (en) cathepsin k inhibition for the treatment and / or prophylaxis of pulmonary hypertension and / or heart failure
IL296338B2 (en) Cxcr4 inhibitor for the treatment of acute respiratory distress syndrome and viral infections
IT202300014322A1 (en) GLUTATHIONE FOR USE IN THE PREVENTION AND/OR TREATMENT OF CARDIOVASCULAR AND RESPIRATORY COMPLICATIONS CONCOMITANT WITH AND/OR CONSEQUENT TO PNEUMONIA
PL4094763T3 (en) Compound for use in prevention and/or treatment of a condition caused by or associated with a coronavirus
IL315901A (en) 5-meo-dmt for use in the treatment of sleep disturbance
IL315897A (en) 5-meo-dmt for use in the treatment of sleep disturbance
MY205329A (en) Transferrin for use in the treatment of hypoxia inducible factor (hif)-related conditions like ischemia
IL312366A (en) Imidazopyridine amides and related compounds for use in the treatment of bacterial infections
TWI800875B (en) Application of lumefantrine and its derivatives in the treatment of coronavirus infection
MX2022002646A (en) FORMULATION OF RUXOLITINIB FOR THE REDUCTION OF ITCHING IN ATOPIC DERMATITIS.
EP3604529A4 (en) MICRO-RNA AND USES THEREOF IN THE PREVENTION AND TREATMENT OF MEDICAL SIGNS AND / OR SYNDROME OF FIBROPLASIA
IL290192A (en) Nitenin analogue compounds and their use in the treatment of chronic and acute pain
IL309072A (en) Interferon-related antigen-binding proteins for use in the treatment or prevention of coronavirus infection
PL4288547T3 (en) Aptamers for use in the treatment of coronaviridae infections
EP4230209C0 (en) PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL COMBINATION AND COMBINATION KIT FOR THE PREVENTION OR TREATMENT OF CHRONIC HEPATITIS B
KR102217518B9 (en) Lactobacillus for the prevention or treatment of periodontitis and its use
DK4346847T3 (en) PLURI-IONIC COMPLEX FOR USE IN THE PREVENTION OR TREATMENT OF NEUROGENIC INFLAMMATION
EP4236931C0 (en) COMPOSITIONS CONTAINING TETRAHYDROCANNABINOL FOR THE TREATMENT OF ACUTE RESPIRATORY INSUFFICIENCY AND/OR ACUTE RESPIRATORY DISTRESS SYNDROME